Hypoxia Imaging With 18F-Fluoroerythronitroimidazole Integrated PET/CT and Immunohistochemical Studies in Non–Small Cell Lung Cancer

Hu, Man; Xing, Ligang; Mu, Dianbin; Yang, Wenfeng; Yang, Guoren; Kong, Li; Yu, Jinming

doi:10.1097/rlu.0b013e318279fd3d

Cited by 38 publications

(47 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Grönroos et al [189] Yang et al [60] NA Hu et al [85] Grönroos et al [189] , Tolvanen et al [190] , Yang et al [60] Hu et al [85] , Li et al [84] Lehtiö et al [99] , Lehtiö et al [191] , Lehtiö et al [192] , Vercellino et al [193] , Yue et al [194] […”

Section: F]ef5unclassified

“…In contrast to these results, other authors did not find a predictive value for [ 18 F]FMISO after chemoradiation [82,83] . In other patients treated with chemoradiation, a threshold of tumor-to-blood ratio > 1.9 for [ 18 F]FETNIM [84,85] and > 3.0 for [Cu]ATSM [86] was associated with poor overall survival and tumor response, respectively. In addition, a number of studies have evaluated the changes in hypoxia tracer uptake during therapy.…”

Section: Determination Of Clinically Relevant Hypoxiamentioning

confidence: 99%

See 1 more Smart Citation

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

Section: F]ef5unclassified

Section: Determination Of Clinically Relevant Hypoxiamentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…A significant but weak correlation between VEGF expression and 18 F-FMISO uptake was observed in newly diagnosed glioma patients, but not in those with recurrent glioma. Hu et al [51] investigated the relationship between [ 18 F]fluoroerythronitroimidazole ( 18 F-FETNIM) uptake and expression of HIF-1 α , VEGF, and glucose transporter 1 (GLUT-1) in nonsmall cell lung cancer. A positive correlation existed between the tumor-to-muscle ratio of 18 F-FETNIM and the expression of each of these HIF-1 α targets.…”

Section: Molecular Imaging Of Hif-1-active Tumor Microenvironmentsmentioning

confidence: 99%

Radiolabeled Probes Targeting Hypoxia-Inducible Factor-1-Active Tumor Microenvironments

Ueda

Saji

2014

The Scientific World Journal

View full text Add to dashboard Cite

Because tumor cells grow rapidly and randomly, hypoxic regions arise from the lack of oxygen supply in solid tumors. Hypoxic regions in tumors are known to be resistant to chemotherapy and radiotherapy. Hypoxia-inducible factor-1 (HIF-1) expressed in hypoxic regions regulates the expression of genes related to tumor growth, angiogenesis, metastasis, and therapy resistance. Thus, imaging of HIF-1-active regions in tumors is of great interest. HIF-1 activity is regulated by the expression and degradation of its α subunit (HIF-1α), which is degraded in the proteasome under normoxic conditions, but escapes degradation under hypoxic conditions, allowing it to activate transcription of HIF-1-target genes. Therefore, to image HIF-1-active regions, HIF-1-dependent reporter systems and injectable probes that are degraded in a manner similar to HIF-1α have been recently developed and used in preclinical studies. However, no probe currently used in clinical practice directly assesses HIF-1 activity. Whether the accumulation of 18F-FDG or 18F-FMISO can be utilized as an index of HIF-1 activity has been investigated in clinical studies. In this review, the current status of HIF-1 imaging in preclinical and clinical studies is discussed.

show abstract

“…Hu et al have tested (18)F-fluoroerythronitroimidazole PET/CT that uses an assessment of tumor hypoxia to evaluate the prognosis on a group of thirty-two NSCLC patiens 154 . A clinical study examining antisense oligodeoxynucleotide binding HIF-1α showed a decrease in HIF-1 protein levels and mRNA levels in some of its target genes in tumor cells 155 .…”

Section: Future Perspectivesmentioning

confidence: 99%

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Doktorova

Hraběta

Khalil

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. The aim of this review is to provide the information about molecular basis of hypoxia-induced chemoresistance, focusing on the possibility of diagnostic and therapeutic use. Results. Hypoxia is a common feature of tumors and represents an independent prognostic factor in many cancers. It is the result of imbalances in the intake and consumption of oxygen caused by abnormal vessels in the tumor and the rapid proliferation of cancer cells. Hypoxia-induced resistance to cisplatin, doxorubicin, etoposide, melphalan, 5-flouoruracil, gemcitabine, and docetaxel has been reported in a number of experiments. Adaptation of tumor cells to hypoxia has important biological effects. The most studied factor responsible for these effects is hypoxia-inducible factor-1 (HIF-1) that significantly contributes to the aggressiveness and chemoresistance of different tumors. The HIF-1 complex, induced by hypoxia, binds to target genes, thereby increasing the expression of many genes. In addition, the expression of hundreds of genes can be also decreased in response to hypoxia in HIF-1 dependent manner, but without the detection of HIF-1 in these genes' promoters. HIF-1 independent mechanisms for drug resistance in hypoxia have been described, however, they are still rarely reported. The first clinical studies focusing on diagnosis of hypoxia and on inhibition of hypoxia-induced changes in cancer cells are starting to yield results. Conclusions. The adaptation to hypoxia requires many genetic and biochemical responses that regulate one another. Hypoxia-induced resistance is a very complex field and we still know very little about it. Different approaches to circumvent hypoxia in tumors are under development.

show abstract

Hypoxia Imaging With 18F-Fluoroerythronitroimidazole Integrated PET/CT and Immunohistochemical Studies in Non–Small Cell Lung Cancer

Abstract: T/Me ratio provides a noninvasive parameter for quantization of (18)F-FETNIM uptake on PET/CT. T/Me ratio is correlated with a worse outcome and with the expression of HIF-1α, GLUT-1, and VEGF, all up-regulated under hypoxic conditions.

Cited by 38 publications

References 20 publications

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Radiolabeled Probes Targeting Hypoxia-Inducible Factor-1-Active Tumor Microenvironments

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Contact Info

Product

Resources

About